Skip to main content
. 2007 Jun 4;51(8):2811–2819. doi: 10.1128/AAC.00200-07

FIG. 7.

FIG. 7.

(A) Comparison of in vivo potencies of PMB and DS-96: dose-dependent increase in survival in mice challenged with a supralethal dose of LPS (200 ng/animal). (B) Schild-type response in vivo: dose dependence of survival in mice challenged with escalating supralethal doses of LPS (200, 500, or 1,000 ng/animal). The LD100 of LPS was determined to be 100 ng/mouse. (C) Time course (pharmacodynamics) of protection conferred by 8 mg/kg of DS-96 administered subcutaneously at various times prior to and following supralethal (200 ng/mouse) LPS challenge.